Physician profile
Joel D Abbott
NPI 1689659021
$14,353.96
in general payments reported to CMS, 2019-2025
35 companies · $2,283 in 2025
The $2,283 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,438 · 2020: $1,385 · 2021: $1,737 · 2022: $2,189 · 2023: $1,933 · 2024: $2,389 · 2025: $2,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,486 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,486.26 |
| Education | $118.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,310.97 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,889.18 | 2019-2025 | |
| Amgen INC. | $1,684.42 | 2019-2025 | Enbrel, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $1,034.93 | 2019-2025 | Orencia |
| Pfizer INC. | $987.48 | 2019-2025 | |
| Janssen Biotech, INC. | $985.64 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $834.96 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $746.72 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $387.85 | 2021-2025 | Acthar |
| Medexus Pharma, INC. | $282.83 | 2019-2020 | |
| Lilly USA, LLC | $282.71 | 2019-2024 | Taltz |
| Horizon Therapeutics Plc | $256.83 | 2019-2022 | |
| Genentech USA, INC. | $217.86 | 2019-2023 | Actemra |
| Radius Health, INC. | $186.11 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.48 | 2020-2025 | Ofev |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $153.12 | 2022-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $128.46 | 2022-2025 | Purified Cortrophin Gel |
| Pacira Therapeutics, INC. | $111.03 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $89.63 | 2022-2024 | Lupkynis |
| Celgene Corporation | $84.43 | 2019 | |
| Fresenius Kabi USA, LLC | $83.79 | 2023-2024 | Idacio |
| Organon LLC | $71.09 | 2024 | |
| Mallinckrodt Enterprises LLC | $64.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $46.43 | 2022-2024 | Strensiq |
| Astellas Pharma US INC | $44.92 | 2021-2023 | Myrbetriq |
| Sobi, INC | $32.48 | 2020-2024 | |
| Tersera Therapeutics LLC | $29.46 | 2025 | Quzyttir |
| Genzyme Corporation | $27.28 | 2025 | |
| Almatica Pharma LLC | $25.28 | 2025 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $24.12 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $21.18 | 2023 | Zilretta |
| Medtronic, INC. | $17.89 | 2022 | |
| Sandoz INC. | $17.33 | 2025 | Hyrimoz |
| Collegium Pharmaceutical, INC. | $12.59 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.